Balancing Risks: Antiplatelet Therapy After Intracerebral Haemorrhage in the STATICH Trial

Highlight

• The STATICH trial evaluated antiplatelet treatment safety after spontaneous intracerebral hemorrhage (ICH).
• Patients starting antiplatelet therapy had numerically more recurrent hemorrhages but fewer major ischemic events.
• The trial was terminated early due to slow recruitment, limiting definitive conclusions.
• Results will inform a collaborative meta-analysis to guide post-ICH antithrombotic management.

Study Background